| Polycomb group (PcG) proteins and human cancers: multifaceted functions and therapeutic implications W Wang, JJ Qin, S Voruganti, S Nag, J Zhou, R Zhang Medicinal research reviews 35 (6), 1220-1267, 2015 | 132 | 2015 |
| Chemistry-first approach for nomination of personalized treatment in lung cancer EA McMillan, MJ Ryu, CH Diep, S Mendiratta, JR Clemenceau, ... Cell 173 (4), 864-878. e29, 2018 | 116 | 2018 |
| Natural Product Ginsenoside 25-OCH3-PPD Inhibits Breast Cancer Growth and Metastasis through Down-Regulating MDM2 W Wang, X Zhang, JJ Qin, S Voruganti, SA Nag, MH Wang, H Wang, ... PLoS One 7 (7), e41586, 2012 | 96 | 2012 |
| The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models W Wang, JJ Qin, S Voruganti, KS Srivenugopal, S Nag, S Patil, H Sharma, ... Nature communications 5 (1), 5086, 2014 | 92 | 2014 |
| Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice W Wang, JJ Qin, S Voruganti, MH Wang, H Sharma, S Patil, J Zhou, ... Gastroenterology 147 (4), 893-902. e2, 2014 | 78 | 2014 |
| Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti … S Voruganti, JJ Qin, S Sarkar, S Nag, IA Walbi, S Wang, Y Zhao, W Wang, ... Oncotarget 6 (25), 21379, 2015 | 65 | 2015 |
| Natural product MDM2 inhibitors: anticancer activity and mechanisms of action JJ Qin, S Nag, S Voruganti, W Wang, R Zhang Current medicinal chemistry 19 (33), 5705-5725, 2012 | 65 | 2012 |
| RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo W Wang, J Cheng, JJ Qin, S Voruganti, S Nag, J Fan, Q Gao, R Zhang Oncotarget 5 (22), 11604, 2014 | 55 | 2014 |
| Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation JJ Qin, W Wang, S Voruganti, H Wang, WD Zhang, R Zhang Oncotarget 6 (5), 2623, 2015 | 54 | 2015 |
| Discovery and characterization of dual inhibitors of MDM2 and NFAT1 for pancreatic cancer therapy W Wang, JJ Qin, S Voruganti, B Nijampatnam, SE Velu, KH Ruan, M Hu, ... Cancer research 78 (19), 5656-5667, 2018 | 45 | 2018 |
| Selective cytotoxicity, inhibition of cell cycle progression, and induction of apoptosis in human breast cancer cells by sesquiterpenoids from Inula lineariifolia Turcz. JJ Qin, HZ Jin, Y Huang, SD Zhang, L Shan, S Voruganti, S Nag, W Wang, ... European journal of medicinal chemistry 68, 473-481, 2013 | 45 | 2013 |
| Inhibitors of 15-prostaglandin dehydrogenase to potentiate tissue repair MI Antczak, Y Zhang, C Wang, J Doran, J Naidoo, S Voruganti, ... Journal of medicinal chemistry 60 (9), 3979-4001, 2017 | 40 | 2017 |
| miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents B Qian, SA Nag, Y Su, S Voruganti, JJ Qin, R Zhang, W Cho Current cancer drug targets 13 (5), 519-541, 2013 | 35 | 2013 |
| Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA JJ Qin, W Wang, S Voruganti, H Wang, WD Zhang, R Zhang Oncotarget 6 (32), 33106, 2015 | 31 | 2015 |
| RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy S Voruganti, F Xu, JJ Qin, Y Guo, S Sarkar, M Gao, Z Zheng, MH Wang, ... Cancer letters 369 (2), 386-395, 2015 | 30 | 2015 |
| Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy JJ Qin, W Wang, S Sarkar, S Voruganti, R Agarwal, R Zhang Oncotarget 7 (22), 32566, 2016 | 26 | 2016 |
| Preclinical evaluation of anticancer efficacy and pharmacological properties of FBA-TPQ, a novel synthetic makaluvamine analog X Zhang, H Xu, X Zhang, S Voruganti, S Murugesan, DH Nadkarni, ... Marine drugs 10 (5), 1138-1155, 2012 | 24 | 2012 |
| Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy JJ Qin, S Sarkar, S Voruganti, R Agarwal, W Wang, R Zhang Journal of biomedical research 30 (4), 322, 2016 | 22 | 2016 |
| Development and validation of a rapid HPLC method for quantitation of SP‐141, a novel pyrido [b] indole anticancer agent, and an initial pharmacokinetic study in mice S Nag, JJ Qin, S Voruganti, MH Wang, H Sharma, S Patil, JK Buolamwini, ... Biomedical Chromatography 29 (5), 654-663, 2015 | 14 | 2015 |
| Tumor-activated benzothiazole inhibitors of stearoyl-CoA desaturase NS Williams, S Gonzales, J Naidoo, G Rivera-Cancel, S Voruganti, ... Journal of Medicinal Chemistry 63 (17), 9773-9786, 2020 | 13 | 2020 |
